Nirvana Life Sciences Inc.
NIRVF
$0.083
$0.0830.00%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 236.60K | 288.80K | 347.00K | 432.10K | 603.70K |
| Depreciation & Amortization | 4.50K | 13.50K | 13.50K | 13.50K | 25.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 261.10K | 337.30K | 410.70K | 531.20K | 710.40K |
| Operating Income | -261.10K | -337.30K | -410.70K | -531.20K | -710.40K |
| Income Before Tax | -398.10K | -517.30K | -596.70K | -826.70K | -1.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.40 | -0.52 | -0.60 | -0.83 | -1.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 700.00 | 1.80K | 1.90K | 2.20K | 3.50K |
| Net Income | -397.40K | -515.40K | -594.60K | -824.30K | -1.09M |
| EBIT | -261.10K | -337.30K | -410.70K | -531.20K | -710.40K |
| EBITDA | -246.80K | -323.20K | -383.00K | -489.60K | -656.30K |
| EPS Basic | -0.08 | -0.11 | -0.12 | -0.18 | -0.28 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.06 | -0.10 | -0.14 |
| EPS Diluted | -0.08 | -0.11 | -0.12 | -0.18 | -0.28 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.06 | -0.10 | -0.14 |
| Average Basic Shares Outstanding | 19.30M | 19.30M | 19.30M | 18.68M | 17.25M |
| Average Diluted Shares Outstanding | 19.30M | 19.30M | 19.30M | 18.68M | 17.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |